



Alzamend Neuro, Inc.

Q4 about inline. Expect positive clinical trials progress in FY25/26 for AL001 and AL002 for Alzheimer's to drive stock. Lowering P/T to \$50.

COMPANY UPDATE

Rating: BUY

Ticker: ALZN

Price: \$2.37

Target: \$50.00
(from \$210)

Q4 about inline: Alzamend recently (on July 30) reported its fiscal Q4 2024 (ending April) results. Net loss was \$0.9 million or EPS of \$(1.21), which compared with our estimates of \$(3.80) and consensus of \$(2.75). There was no Q4 guidance. Alzamend is an early/clinical stage drug development company so it generates no revenue.

Operating expenses: Operating expenses were \$0.9 million, vs. \$2.7 million in Q3 FY24.

No guidance: Management did not provide forward guidance, but we believe ~\$3 million to be a reasonable near term quarterly cash burn rate.

Adjusting estimates: We are adjusting our FY25 EPS estimate to \$(14.27) from \$(21.61).

Focus on Alzheimer's: Alzamend has two novel therapeutic drug candidates for Alzheimer's disease. Alzheimer's disease is a progressive neurologic disease that causes brain cells to die and memory or other cognitive impairments. Alzheimer's is the leading cause of dementia, a decline in mental functions that negatively affects a person's ability to function independently. Of the ten most fatal diseases in the U.S., Alzheimer's is the only one with no known cure, ability to slow progression, or means of prevention.

AL001: AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, proline, and salicylate to help combat Alzheimer's by preventing cognitive deficits, depression, irritability, and improving associative learning and memory.

AL002: AL002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.

Positive Top-line data for Phase 2 clinical trial for AL001: In May 2022, the company initiated a Phase 2 study for AL001 involving Alzheimer's patients. In June 2023, the company reported positive Top-line results from this study. The company has two more Phase II clinical studies for AL001 for Alzheimer's patients expected to start in 2025.

BD, MDD, and PTSD trials: The company has filed an IND for the treatment of Bipolar Disorder (BD), Major Depressive Disorder (MDD), and Post-Traumatic Stress Disorder (PTSD). It has received "study may proceed" for each of them and expect to start clinical trials in 2025 with Massachusetts General Hospital leading the studies.

AL002 trial started: The company has started its clinical trials for AL002 (in April 2023) to treat mild to moderate dementia of the Alzheimer's type. After a pause in February 2024, the trial is expected to resume in Q4 2024.

Clinical trials can be catalyst: Alzamend anticipates starting/finishing its various clinical trials over the next year (in FY25/26). We believe achieving key milestones and positive data will likely be catalysts for the stock.

Balance sheet: In Q4, the company had ~\$0 million in cash and no debt. We expect the company will need to raise cash soon (in the current quarter) as it has several financing deals already in place.

Reverse stock split: The company effected a 1-for-10 reverse stock split in July 2024.

Current valuation attractive: We are maintaining our BUY rating, but lowering our 12-month price target to \$50 from \$210, based on a NPV analysis, representing significant upside from the current share price. We believe this valuation fairly balances out the high risks with large upside opportunities.

Company Description

Based in Atlanta, GA, Alzamend Neuro is a clinical-stage biopharmaceutical company focused on novel medicines to prevent, treat, and cure Alzheimer's.

United States
Healthcare

August 28, 2024

Edward Woo, CFA
(561) 327-9435
ewoo@ascendant.com

Stock Data

Exchange:	NasdaqCM
52-week Range:	\$1.84 – 44.85
Shares Outstanding (million):	0.8
Market cap (\$million):	\$2
EV (\$million):	\$2
Debt (\$million):	\$0
Cash (\$million):	\$0
Avg. Daily Trading Vol. (\$million):	\$7
Float (million shares):	0.7
Short Interest (million shares):	~0
Dividend, annual (yield):	\$0 (NA%)

Revenues (US\$ million)

	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> <u>(Old)</u>	<u>2026E</u> <u>(Cur.)</u>	<u>2026E</u> <u>(Old)</u>
Q1 Jul	0E		0E	
Q2 Oct	0E		0E	
Q3 Jan	0E		0E	
Q4 Apr	<u>0E</u>		<u>0E</u>	
Total	0E		0E	
EV/Revs	N/A		N/A	

Earnings per Share (pro forma)

	<u>2025E</u> <u>(Cur.)</u>	<u>2025E</u> <u>(Old)</u>	<u>2026E</u> <u>(Cur.)</u>	<u>2026E</u> <u>(Old)</u>
Q1 Jul	(2.38)E	(5.51)E	(4.25)E	
Q2 Oct	(2.38)E	(5.44)E	(4.25)E	
Q3 Jan	(4.76)E	(5.37)E	(4.25)E	
Q4 Apr	<u>(4.76)E</u>	<u>(5.29)E</u>	<u>(4.25)E</u>	
Total	<u>(14.27)E</u>	<u>(21.61)E</u>	<u>(17.00)E</u>	
P/E	N/A		N/A	

*Reflects a 1:10 reverse stock split in July 2024.

Important Disclosures

Ascendant Capital Markets LLC seeks to do business with companies covered by its research team. Consequently, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making an investment decision.

For analyst certification and other important disclosures, refer to the Disclosure Section, located at the end of this report, beginning on page 15.

Exhibit 1: Alzamend Neuro Overview

Company Overview	
<p style="text-align: center;">Company History</p> <p>Clinical-stage biopharmaceutical company dedicated to:</p> <ul style="list-style-type: none"> Researching, developing and commercializing preventions, treatments and cures for Alzheimer's Disease, Bipolar Disorder, Major Depressive Disorder, and Post-Traumatic Stress Disorder via the two therapeutics licensed from the University of South Florida Research Foundation, Inc., one of the top 20 institutions in the nation for patented research and their portfolio of proprietary solutions. 	<p style="text-align: center;">Current Pipeline</p> <p>AL001 (aka LISPRO):</p> <ul style="list-style-type: none"> a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline for the treatment of Alzheimer's' Disease, BD, MDD and PTSD <p>ALZN002 (aka E22W):</p> <ul style="list-style-type: none"> a cell-based therapeutic vaccine that seeks to restore the ability of the patients' immunological system to combat Alzheimer's Disease.

Source: Company reports.

Exhibit 2: Alzheimer's Disease

OVERVIEW OF ALZHEIMER'S DISEASE

Alzheimer's Disease



Key Statistics:

7th leading cause of death in the United States

Between 2000 and 2019, deaths from heart disease have **decreased 7.3%** while deaths from Alzheimer's Disease have **increased 145%**

13 million Americans are projected to be living with Alzheimer's Disease by 2050

1-in-9 Americans over the age of 65 are estimated to be afflicted with Alzheimer's Disease



Alzheimer's Disease:

Alzheimer's Disease is an **irreversible, progressive brain disorder** that **slowly destroys memory** and **cognitive skills**, and eventually the **ability to carry out the simplest tasks**.

In most people with Alzheimer's Disease, symptoms first appear in their early to mid-60's. Estimates vary, but experts suggest that more than **6.5 million Americans** may have Alzheimer's Disease, considered by many as "**the most feared**" disease.

Alzheimer's Disease has **no current cure**, but five treatments for symptoms are available today while research continues.

Source: Company reports.


Exhibit 3: Alzamend Neuro Product Pipeline (as of August 2024)

Product Candidate	Indication	Pre-Clinical	Phase I	Phase II	Phase III	FDA Approval
AL001	• Alzheimer's Disease	→			<ul style="list-style-type: none"> • Reported Topline data for the Phase IIA MAD study in June 2023 • Anticipate initiating a Phase II clinical studies in Alzheimer's patients in 2025 	
	• Bipolar Disorder	→			<ul style="list-style-type: none"> • Received "Study May Proceed" notification from the FDA in September 2023 to Initiate a Phase II Clinical Trial • Anticipate initiating a Phase II clinical studies in BD patients in 2025 	
	• Major Depressive Disorder	→			<ul style="list-style-type: none"> • Received "Study May Proceed" notification from the FDA in November 2023 to Initiate a Phase II Clinical Trial • Anticipate initiating a Phase II clinical studies in MDD patients in 2025 	
	• Post-Traumatic Stress Disorder	→			<ul style="list-style-type: none"> • Received "Study May Proceed" notification from the FDA in December 2023 to Initiate a Phase II Clinical Trial • Anticipate initiating a Phase II clinical studies in PTSD patients in 2025 	
ALZN002	• Alzheimer's Disease	→			<ul style="list-style-type: none"> • Initiated Phase I/IIA Clinical Trial in March 2023, paused in February 2024 and expected to resume in 2H 2024 	

Source: Company reports.

Exhibit 4: Biomarkers of Alzheimer's Disease

Alzamend Neuro, Inc.
Biomarkers of Alzheimer's Disease



Our lead product candidate that we have licensed and will first move to clinical development in humans is an ionic cocrystal of lithium for the treatment of Alzheimer's and other neurodegenerative diseases and psychiatric disorders.

Source: Company reports.

Exhibit 5: What is Alzheimer's Disease?



The brain has three main parts:



The **cerebrum** fills up most of your skull. It is involved in remembering, problem solving, thinking, and feeling. It also controls movement.



The **cerebellum** sits at the back of your head, under the cerebrum. It controls coordination and balance.



The **brain stem** sits beneath your cerebrum in front of your cerebellum. It connects the brain to the spinal cord and controls automatic functions such as breathing, digestion, heart rate and blood pressure.

Alzheimer's Changes the Whole Brain

Alzheimer's disease leads to nerve cell death and tissue loss throughout the brain. Over time, the brain shrinks dramatically, affecting nearly all its functions.

These images show:



A brain without the disease.



A brain with advanced Alzheimer's.






How the two brains compare.


Source: Alzheimer's Association

Exhibit 6: AL001 (LISPRO)

AL001 (aka LISPRO)



- **Narrow therapeutic window** that requires **regular blood monitoring** of plasma lithium levels and blood chemistry by a clinician **to mitigate adverse events**
- **Multiple administrations** throughout the day are required to safely reach therapeutic plasma concentrations
- **Suffer from chronic toxicity, poor physicochemical properties** and **poor brain bioavailability**



- AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of **lithium, salicylate, and proline**.
- AL001 exhibits **improved non-clinical pharmacokinetics** and **bioavailability** compared to the currently FDA approved lithium drugs on the market
- AL001 exhibits **improved non-clinical brain bioavailability**, without demonstrating an initial spike in lithium concentration that is associated with negative side effects of treatment
- AL001 **nonclinical brain penetration/persistence** may translate to patients resulting in lithium dose sparing properties with enhanced overall safety and reduced or eliminated need for therapeutic drug monitoring.

Alzamend Neuro, Inc. information cannot be disclosed or reprinted without prior written permission.

19

Source: Company reports.

Exhibit 7: AL001 (LISPRO) Preclinical Studies

OUR SCIENCE - NON-CLINICAL

AL001 (aka LISPRO)



The results of our preclinical studies, conducted from May 2016 to June 2017, are summarized below:

- AL001 had no effect on renal COX2 activity (Tg-Ctrl vs. AL001: $p > 0.05$), a biomarker of renal toxicity, while markedly **reducing abnormal biomarkers** associated with Alzheimer's Disease **by 50%**; **beta-amyloid pathology, tau phosphorylation** and **neuro-inflammation** (Tg-Ctrl vs. AL001: $p < 0.01$) (FIGS. 14A/B-15A/B).
- AL001 treatment **did not induce tissue pathological damage in the heart, kidneys, liver or lungs** by a general autopsy (Tg-Ctrl vs. AL001: $p > 0.05$). In contrast, **equimolar doses** (using a similar structure of moles but different active pharmaceutical ingredient) **of lithium carbonate enhanced renal COX2 expression** while **having little or no impact on Alzheimer's Disease pathology** (Tg-Ctrl vs. LC: $p < 0.01$).
- AL001, at the effective dose, **yielded 50% higher lithium levels** (LC vs. AL001; $p < 0.01$) **in the brain** compared with equimolar doses of lithium carbonate (AL001 vs. LC; $p < 0.05$), while producing low nontoxic steady state levels in the body.




FIG. 14A & 14B: Beta Amyloid Burden




FIG. 14B




FIG. 15A & 15B: Tau Phosphorylation Burden




FIG. 15B

Source: Company reports.

Exhibit 8: AL001 (LISPRO) Update

Study No.	Study Title	Description	Status
AL001-ALZ02 (US)	A Multiple-dose, Steady-state, Double-blind, Ascending Dose Safety, Tolerability, Pharmacokinetic Study of AL001 in Patients with Mild to Moderate Alzheimer's Disease and Healthy Adult Subjects	<ul style="list-style-type: none"> Primary: To evaluate the safety and tolerability of AL001 under multiple-dose, steady-state conditions in Alzheimer's subjects and healthy adult subjects Secondary: To characterize the maximum tolerated dose (MTD) of AL001 in subjects with mild to moderate Alzheimer's Disease and healthy adult subjects Exploratory: To explore the difference in pharmacokinetic profile between the non-elderly vs. elderly subjects (healthy subjects only). For Alzheimer's Disease subject cohorts (Cohorts 1,2b, 3b, 4b, and 5b), determination of qualitative and quantitative evaluations of Alzheimer's Disease subject desirable characteristics for future Phase II and III clinical studies to: <ul style="list-style-type: none"> Facilitate recruitment into subsequent AL001 clinical trials Facilitate trial-adherence to completion of study requirements including treatment adherence 	<ul style="list-style-type: none"> Reported Topline data of Phase IIA Multiple Ascending Dose Clinical Trial in June 2023. (www.clinicaltrials.gov, identifier: NCT05363293)

Alzamend Neuro, Inc. Information may be disclosed or revised without prior written notification.

16

Source: Company reports.

Exhibit 9: AL002 (E22W)

AL002 (CAO22W)

A cell-based therapeutic vaccine which seeks to restore the ability of the patient's immunological system to combat Alzheimer's Disease



Hypothesis:

- AL002 is intended to **elicit an immune response** to **produce anti-amyloid antibodies**, which can then neutralize circulated beta-amyloids and prevent additional plaque build-up.
- AL002 is a **patient-specific therapy** where the patient undergoes leukapheresis, a nonsurgical treatment used to reduce the quantity of white blood cells in the bloodstream, **to isolate peripheral blood monocytes** that are subsequently **matured into dendritic cells ("DCs")** using an **IL4+ GM-CSF cocktail**.
- The **DCs** are **incubated** with a modified amyloid beta (A β) peptide ("**AL002 peptide**") to sensitize them, and then **administered to the same patient**.

Source: Company reports.

Exhibit 10: Overview of AL002 (E22W)

Overview of ALZN002 (aka E22W)




FIG. 5A

The Results

- Our goal is to develop an Alzheimer's A β vaccine candidate that will be devoid of the problems associated with current vaccine therapies. Our studies concluded the successful vaccination of mice with adjuvant-free mutated beta amyloid peptides have significant advantages over both native beta amyloid and the use of adjuvant.
- 10 weeks old female BALB/c mice were housed in Varian standard cages including amber igloos and vaccinated when 14 weeks old.
- Differently mutated A β 1-42 peptides were used for each group and a 1times.PBS (also containing 10% DMSO) as a control group.
- Mice vaccinated with various mutated A β 1-42 peptides **induce antibody responses** after two inoculations, while no antibody can be detected in the control group (FIG. 5A).
- All antibodies induced by the peptide injection **bind to the same epitope**. There is no difference in recognition between the various anti-sera and peptides such that all anti-sera recognize the 1-16 epitope on all peptides.
- Demonstrate definite advantages over previous vaccination protocols, which **strongly support our Adjuvant-Free Vaccine Hypothesis**.
- The data clearly show that wild type and mutated A β peptide administered without adjuvant induce a **strong and long-lasting antibody response**.
- The **first use of adjuvant-free A β** as Alzheimer's vaccine and demonstration that T-cell epitope mutation will contribute to either Th1 or Th2 response. Those peptides will have outstanding promise for the treatment of Alzheimer's Disease.

Source: Company reports.

Exhibit 11: ALZN002 Phase I/IIA Trial

Study No.	Study Title	Description	Status
ALZN002-01(US)	A Randomized, Double-blind, Placebo-controlled, Parallel group, Phase I/IIA Study to Assess the Safety, Tolerability, and Efficacy of Autologous Amyloid Beta Mutant Peptide-Pulsed Dendritic Cells (ALZN002) in Subjects with Mild-to-Moderate Dementia of the Alzheimer's Type	<ul style="list-style-type: none"> Primary: <ul style="list-style-type: none"> To assess the safety and tolerability of ALZN002 compared with placebo when administered as IV infusion and ID injection in subjects with mild to moderate AD Secondary: <ul style="list-style-type: none"> To evaluate the immunogenicity of ALZN002 specific to generation of anti-Aβ antibodies To determine the effect of ALZN002 on Amyloid-Related Imaging Abnormalities (ARIA) as a putative biomarker of treatment safety Exploratory: <ul style="list-style-type: none"> To assess the utility of multiple immune biomarkers as surrogates for safety and efficacy of ALZN002. To assess the preliminary efficacy of ALZN002 treatment on amyloid markers as observed by amyloid positron emission tomography (PET). 	Phase I/IIA Clinical Trial Initiated in March 2023 (www.clinicaltrials.gov, identifier: NCT05834296), paused in February 2024 and expected to resume in 2H 2024

Source: Company reports.

Exhibit 12: Market Opportunity for AL001 and AL002

COMPETITIVE LANDSCAPE

Overview of Market Opportunity for AL001 and AL002



Patient Population	United States	Global (Including US)
MDD	21 Million ¹	280 Million ²
PTSD	9 Million ¹	284 Million ²
Alzheimer's Disease	6.5 Million ¹	55 Million ²
BD	7 Million ¹	45 Million ²
Total Patient Population	43.5 Million	664 Million

Source: Company reports.

Exhibit 13: Market Opportunities for BD, MDD, PTSD

Bipolar Disorder



Key Statistics:

An estimated **7 Million** adults in the US and over **45 Million** globally experience **Bipolar Disorder** each year

Of adults who live with **Bipolar Disorder**, almost **83%** experience significant disruption in their physical or mental abilities

The average age of onset is **25 years old**. People ages **18 to 29 years old** had the highest rates of bipolar disorder (**4.7%**) followed by 30- to 44-year-olds (**3.5%**)

The risk of **suicide** is extremely high in people with bipolar disorder with **15% to 17% committing suicide**

Bipolar Disorder:

Bipolar Disorder is a mental illness that causes unusual shifts in a person's **mood, energy, activity levels, and concentration**.

The **three primary types** of bipolar disorders are bipolar I disorder, bipolar II disorder, and cyclothymic disorder.

- **Bipolar I:** Characterized by episodes of mania that last at least seven days and may require hospitalization.
- **Bipolar II:** Defined by a pattern of depressive and hypomanic episodes. Hypomania is a mood elevation that increases energy, agitation, and pressured speech.
- **Cyclothymic disorder:** More frequent shifts between mood swings, which is called rapid cycling. The highs are consistent with hypomania symptoms and the lows are mild to moderate depression.

Major Depressive Disorder



Key Statistics:

An estimated **21 Million** adults in U.S. had at least one **major depressive** episode in 2021. This number represented **8.3%** of all U.S. adults

Women are almost twice as likely as men to have had depression and women who have **MDD** can have an increased risk of **Low Bone Mass** which can lead to fractures and can contribute to their risk for **osteoporosis**

An estimated **5.0 million adolescents aged 12 to 17** in the United States had at least one major depressive episode. This number represented **20.1% of the U.S. population aged 12 to 17**

Adults with a **depressive disorder** or symptoms have a **64% greater risk** of developing **coronary artery disease**

Major Depressive Disorder:

Major Depressive Disorder (MDD), commonly known as **clinical depression**, is one of the most common mental disorders worldwide. Many different factors can contribute to a person's depressive state and depression is often an **overlapping diagnosis** along with **other medical conditions and/or mental disorders**.

The most prominent **symptoms** of major depression are a **severe and persistent low mood, profound sadness, or a sense of despair**. A major depressive episode (MDE) is a time-period characterized by symptoms of **major depression**.

Depression is the cause of over **two-thirds** of the **30,000 reported suicides** in the U.S. each year.

<https://www.nimh.nih.gov/health/statistics/major-depression>
<https://www.dbaalliance.org/education/depression/statistics>
<https://www.singlecare.com/blog/2020/05/depression-statistics/>

Post-Traumatic Stress Disorder



Key Statistics:

About **5 out of every 100 adults** (or 5%) in the U.S. has PTSD in **any given year**. In 2020, about **13 million** Americans had PTSD.

Women are more likely to develop **PTSD** than **men**. About **8 of every 100 women** (or 8%) and **4 of every 100 men** (or 4%) will have PTSD at some point in their life. This is in part due to the types of **traumatic events** that women are more likely to experience—such as sexual assault—compared to men.

Veterans are more likely to have PTSD than **civilians**. Veterans who **deployed** to a **war zone** are also more likely to have PTSD than those who did not deploy.

Post-Traumatic Stress Disorder:


PTSD is a **mental and behavioral disorder** that can develop because of exposure to a **traumatic event**, such as sexual assault, warfare, traffic collisions, child abuse, domestic violence, or other **threats on a person's life**.

Symptoms may include disturbing **thoughts, feelings, or dreams** related to the events, **mental or physical distress** in response to trauma-related cues, attempts to avoid trauma related cues, alterations in the way a person thinks and feels, and an increase in the fight-or-flight response.

These symptoms last for more than a month after the event. A person with **PTSD** is at a **higher risk of suicide** and intentional self-harm.

Source: Company reports.

Exhibit 14: Alzamend Neuro, Inc. Stock Price (3-years since IPO in June 2021)



*Reflects a 1:15 reverse stock split in October 2023

*Reflects a 1:10 reverse stock split in July 2024

Source: <https://bigcharts.marketwatch.com/>

Exhibit 15: Consensus Expectations (as of July 30, 2024)

	Revenue			EPS	
	2024E	2025E		2024E	2025E
Q1 Jul	\$0A	\$0E	Q1 Jul	\$(5.38)A	\$(5.50)E
Q2 Oct	\$0A		Q2 Oct	\$(4.43)A	
Q3 Jan	\$0A		Q3 Jan	\$(3.77)A	
Q4 Apr	\$0E		Q4 Apr	\$(2.75)E	
Total	\$0E	\$0E	Total	\$(14.50)E	\$(14.45)E

*Quarterly estimates may not add to annual estimates due to variations in contributing estimates and rounding.

*Reflects a 1:15 reverse stock split in October 2023

*Reflects a 1:10 reverse stock split in July 2024

Source: Company report, LSEG, and Ascendant Capital Markets estimates

FINANCIAL MODEL

Alzamend Neuro, Inc.

Income Statement (\$ mils)	Jul-22	Oct-22	Jan-23	Apr-23	2023	Jul-23	Oct-23	Jan-24	Apr-24	2024	Jul-24	Oct-24	Jan-25	Apr-25	2025	Jul-25	Oct-25	Jan-26	Apr-26	2026
Fiscal Year End: April 30	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E
Total Revenue	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cost of Revenues	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Gross Profit	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Research and development	1.4	1.5	2.9	1.6	7.4	2.4	2.0	1.9	0.2	6.5	1.0	1.0	2.0	2.0	6.0	2.0	2.0	2.0	2.0	8.0
General and administrative	1.7	1.6	2.5	1.7	7.4	1.2	0.9	0.8	0.7	3.5	1.0	1.0	2.0	2.0	6.0	2.0	2.0	2.0	2.0	8.0
Restructuring and other					0.0					0.0					0.0					0.0
Total operating expenses	3.0	3.1	5.4	3.3	14.9	3.5	2.9	2.7	0.9	9.9	2.0	2.0	4.0	4.0	12.0	4.0	4.0	4.0	4.0	16.0
Operating income (loss)	(3.0)	(3.1)	(5.4)	(3.3)	(14.9)	(3.5)	(2.9)	(2.7)	(0.9)	(9.9)	(2.0)	(2.0)	(4.0)	(4.0)	(12.0)	(4.0)	(4.0)	(4.0)	(4.0)	(16.0)
Interest income (expense)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	(0.0)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other income (expense)					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income before income taxes	(3.0)	(3.1)	(5.4)	(3.3)	(14.9)	(3.5)	(2.9)	(2.7)	(0.9)	(9.9)	(2.0)	(2.0)	(4.0)	(4.0)	(12.0)	(4.0)	(4.0)	(4.0)	(4.0)	(16.0)
Income taxes					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income (loss)	(3.0)	(3.1)	(5.4)	(3.3)	(14.9)	(3.5)	(2.9)	(2.7)	(0.9)	(9.9)	(2.0)	(2.0)	(4.0)	(4.0)	(12.0)	(4.0)	(4.0)	(4.0)	(4.0)	(16.0)
Nonrecurring/noncash adjustments					0.0					0.0					0.0					0.0
Net income (pro forma)	(3.0)	(3.1)	(5.4)	(3.3)	(14.9)	(3.5)	(2.9)	(2.7)	(0.9)	(9.9)	(2.0)	(2.0)	(4.0)	(4.0)	(12.0)	(4.0)	(4.0)	(4.0)	(4.0)	(16.0)
EBITDA	(2.2)	(2.4)	(3.9)	(2.8)	(11.3)	(3.1)	(2.6)	(2.5)	(0.8)	(8.9)	(1.9)	(1.9)	(3.9)	(3.9)	(11.6)	(3.9)	(3.9)	(3.9)	(3.9)	(15.6)
Shares, Basic	0.6	0.6	0.7	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
Shares, Diluted	0.6	0.6	0.7	0.6	0.7	0.7	0.7	0.7	0.7	0.7	0.8	0.8	0.8	0.8	0.8	0.9	0.9	0.9	0.9	0.9
EPS Basic (pro forma)	(\$4.67)	(\$4.79)	(\$8.28)	(\$5.11)	(\$22.89)	(\$5.38)	(\$4.43)	(\$3.77)	(\$1.21)	(\$14.70)	(\$2.38)	(\$2.38)	(\$4.76)	(\$4.76)	(\$14.27)	(\$4.25)	(\$4.25)	(\$4.25)	(\$4.25)	(\$17.00)
EPS Diluted (pro forma)	(\$4.67)	(\$4.79)	(\$8.28)	(\$5.11)	(\$22.89)	(\$5.38)	(\$4.43)	(\$3.77)	(\$1.21)	(\$14.70)	(\$2.38)	(\$2.38)	(\$4.76)	(\$4.76)	(\$14.27)	(\$4.25)	(\$4.25)	(\$4.25)	(\$4.25)	(\$17.00)
Margins																				
Gross margin																				
Research and development																				
General and administrative																				
Operating margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
Tax rate, GAAP	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
Net margin	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM	NM
YY % change																				
Total Revenue																				
Gross margin																				
Research and development	50%	-12%	231%	-1%	43%	72%	30%	-34%	-89%	-13%	-58%	-50%	5%	990%	-7%	100%	100%	0%	0%	33%
General and administrative	19%	-14%	51%	-25%	4%	-30%	-42%	-70%	-60%	-53%	-14%	11%	166%	200%	72%	100%	100%	0%	0%	33%
Operating income (loss)	32%	-13%	112%	-15%	21%	16%	-7%	-51%	-74%	-33%	-43%	-31%	50%	371%	21%	100%	100%	0%	0%	33%
Net income (loss)	31%	-14%	111%	-15%	20%	16%	-7%	-51%	-74%	-33%	-43%	-31%	50%	370%	21%	100%	100%	0%	0%	33%
EPS Diluted (pro forma)	14%	-17%	102%	-17%	10%	15%	-7%	-54%	-76%	-36%	-56%	-46%	26%	294%	-3%	79%	79%	-11%	-11%	19%

Reflects a 1:15 reverse stock split in October 2023

Reflects a 1:10 reverse stock split in July 2024

Source: Company reports and Ascendant Capital Markets estimates.

Alzamend Neuro, Inc.

Balance Sheet (\$ mils)	Jul-22	Oct-22	Jan-23	Apr-23	Jul-23	Oct-23	Jan-24	Apr-24	Jul-24	Oct-24	Jan-25	Apr-25	Jul-25	Oct-25	Jan-26	Apr-26
Fiscal Year End: April 30	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Assets																
Cash and cash equivalents	11.5	9.2	7.4	5.1	1.7	0.2	0.3	0.4	0.5	(1.4)	(5.5)	(9.4)	(13.4)	(17.4)	(21.4)	(25.5)
Short term investments									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income taxes									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Prepaid expenses and other	0.6	1.2	1.0	0.7	0.7	0.6	0.3	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Total current assets	12.1	10.3	8.4	5.8	2.4	0.8	0.6	0.5	0.5	(1.4)	(5.4)	(9.3)	(13.4)	(17.3)	(21.3)	(25.4)
Property and equipment, net	0.1	0.1	0.1	0.1	0.2	0.2	0.2	0.2	0.2	0.2	0.3	0.3	0.4	0.4	0.5	0.7
Intangibles, net									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total assets	12.2	10.4	8.5	5.9	2.6	1.0	0.8	0.6	0.7	(1.2)	(5.1)	(9.0)	(13.0)	(16.9)	(20.8)	(24.7)
Liabilities and stockholders' equity																
Accounts payable	1.0	0.6	2.6	2.9	2.7	3.7	3.8	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9	2.9
Accrued expenses									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred income tax									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other		1.0							0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Short term debt							0.3		0.3	0.3	0.3	0.3	0.3	0.3	0.3	0.3
Total current liabilities	1.0	1.6	2.6	2.9	2.7	3.7	3.8	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2	3.2
Deferred income taxes									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Warrant liabilities							0.7		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other long term liabilities									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long term debt									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total other liabilities	0.0	0.0	0.0	0.0	0.0	0.0	0.7	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Preferred stock							0.5		0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Common stock	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.2	0.2	0.3	0.4	0.5	0.6	0.7
Additional paid-in capital	58.3	59.0	61.5	62.0	62.4	62.7	49.0	51.4	51.4	51.4	51.4	51.4	51.4	51.4	51.4	51.4
Retained earnings	(32.2)	(35.3)	(40.8)	(44.1)	(47.6)	(50.5)	(53.2)	(54.0)	(56.0)	(58.0)	(62.0)	(66.0)	(70.0)	(74.0)	(78.0)	(82.0)
Accumulated other comprehensive income									0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other	(14.9)	(14.9)	(14.9)	(14.9)	(14.9)	(14.9)			2.0	2.0	2.0	2.0	2.0	2.0	2.0	2.0
Total stockholders' equity	11.2	8.8	5.9	3.0	(0.1)	(2.7)	(3.8)	(2.6)	(2.5)	(4.4)	(8.4)	(12.3)	(16.2)	(20.1)	(24.0)	(27.9)
Total stockholders' equity and liabilities	12.2	10.4	8.5	5.9	2.6	1.0	0.8	0.6	0.7	(1.2)	(5.1)	(9.0)	(13.0)	(16.9)	(20.8)	(24.7)

Balance Sheet Drivers

	Jul-22	Oct-22	Jan-23	Apr-23	Jul-23	Oct-23	Jan-24	Apr-24	Jul-24	Oct-24	Jan-25	Apr-25	Jul-25	Oct-25	Jan-26	Apr-26
	Q1A	Q2A	Q3A	Q4A	Q1A	Q2A	Q3A	Q4A	Q1E	Q2E	Q3E	Q4E	Q1E	Q2E	Q3E	Q4E
Book & Cash Value (per share)																
Book Value per Share (diluted)	17.21	13.52	8.94	4.71	(0.17)	(4.09)	(5.37)	(3.68)	(2.99)	(5.27)	(9.93)	(14.59)	(17.20)	(21.37)	(25.53)	(29.70)
Cash per Share (diluted)	17.74	14.13	11.25	7.95	2.58	0.30	0.40	0.53	0.56	(1.71)	(6.53)	(11.17)	(14.29)	(18.44)	(22.75)	(27.06)
Net cash per Share (diluted)	17.74	14.13	11.25	7.95	2.58	0.30	0.40	0.11	0.20	(2.07)	(6.88)	(11.53)	(14.61)	(18.76)	(23.07)	(27.38)

Source: Company reports and Ascendant Capital Markets estimates

Alzamend Neuro, Inc.


Cash Flow Statement (\$ mils)	Jul-22	Oct-22	Jan-23	Apr-23	2023	Jul-23	Oct-23	Jan-24	Apr-24	2024	Jul-24	Oct-24	Jan-25	Apr-25	2025	Jul-25	Oct-25	Jan-26	Apr-26	2026	
Fiscal Year End: April 30	Q1A	Q2A	Q3A	Q4A	FY-A	Q1A	Q2A	Q3A	Q4A	FY-A	Q1E	Q2E	Q3E	Q4E	FY-E	Q1E	Q2E	Q3E	Q4E	FY-E	
Cash flow from operating activities																					
Net income	(3.0)	(3.1)	(5.4)	(3.3)	(14.9)	(3.5)	(2.9)	(2.7)	(0.9)	(9.9)	(2.0)	(2.0)	(4.0)	(4.0)	(12.0)	(4.0)	(4.0)	(4.0)	(4.0)	(16.0)	
Depreciation	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.0	0.0	0.1	
Amortization					0.0					0.0					0.0					0.0	
Debt related amortization expense					0.0				0.0	0.0					0.0					0.0	
Stock comp	0.9	0.7	1.5	0.5	3.6	0.4	0.3	0.2	0.1	1.0	0.1	0.1	0.1	0.1	0.3	0.1	0.1	0.1	0.1	0.3	
Deferred income taxes					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in fair value of warrant liability					0.0					0.0					0.0					0.0	
Writedowns and impairments					0.0					0.0					0.0					0.0	
Other gains/losses					0.0					0.0					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Changes in operating assets and liabilities:																					
Prepaid expenses & other curre	(0.2)	0.4	0.1	0.3	0.6	(0.3)	0.1	0.3	0.5	0.6	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Other assets					0.0	0.2			(0.2)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Accounts payable	(0.1)	(0.4)	2.0	0.2	1.7	(0.1)	0.9	0.2	(0.9)	0.1	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Accrued expenses					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Other liabilities					0.0					0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Net cash (used in) provided by	(2.5)	(2.3)	(1.8)	(2.2)	(8.9)	(3.3)	(1.5)	(2.0)	(1.4)	(8.3)	(1.9)	(1.9)	(3.9)	(3.9)	(11.6)	(3.9)	(3.9)	(3.9)	(3.9)	(15.6)	
Cash flow from investing activities																					
Purchases of property and equipment					0.0	(0.1)				(0.1)	0.0	0.0	(0.1)	0.0	(0.1)	(0.1)	0.0	(0.1)	(0.1)	(0.4)	
Purchases of short-term investments					0.0					0.0					0.0					0.0	
Acquisitions					0.0					0.0					0.0					0.0	
Other					0.0					0.0					0.0					0.0	
Net cash used in investing activ	0.0	0.0	0.0	0.0	0.0	(0.1)	0.0	0.0	0.0	(0.1)	0.0	0.0	(0.1)	0.0	(0.1)	(0.1)	0.0	(0.1)	(0.1)	(0.4)	
Cash flow from financing activities																					
Issuance of debt					0.0				0.3	0.3	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Repayment of debt					0.0					0.0					0.0					0.0	
Issuance of stock					0.0		0.0	2.1	1.2	3.4	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Proceeds from stock option exercises				0.0	0.0					0.0					0.0					0.0	
Other					0.0					0.0	2.0				2.0					0.0	
Dividends and distributions					0.0					0.0					0.0					0.0	
Cash provided by (used in) fina	0.0	0.0	0.0	0.0	0.0	0.0	0.0	2.1	1.5	3.7	2.0	0.0	0.0	0.0	2.0	0.0	0.0	0.0	0.0	0.0	
Effect of exchange rate on cash					0.0					0.0					0.0					0.0	
Net increase (decrease) in cash	(2.5)	(2.3)	(1.8)	(2.2)	(8.9)	(3.4)	(1.5)	0.1	0.1	(4.8)	0.1	(1.9)	(4.1)	(3.9)	(9.8)	(4.1)	(3.9)	(4.1)	(4.1)	(16.1)	
Beginning cash and equivalents	14.1	11.5	9.2	7.4	14.1	5.1	1.7	0.2	0.3	5.1	0.4	0.5	(1.4)	(5.5)	0.4	(9.4)	(13.4)	(17.4)	(21.4)	(9.4)	
Ending cash and equivalents	11.5	9.2	7.4	5.1	5.1	1.7	0.2	0.3	0.4	0.4	0.5	(1.4)	(5.5)	(9.4)	(9.4)	(13.4)	(17.4)	(21.4)	(25.5)	(25.5)	

Source: Company reports and Ascendant Capital Markets estimates

ANALYST CERTIFICATION

Each analyst hereby certifies that the views expressed in this report reflect the analyst's personal views about the subject securities or issuers. Each analyst also certifies that no part of the analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The analyst who prepared this report is compensated based upon the overall profitability of Ascendant Capital Markets, LLC, which may, from time to time, include the provision of investment banking, financial advisory and consulting services. Compensation for research is based on effectiveness in generating new ideas for clients, performance of recommendations, accuracy of earnings estimates, and service to clients.

Alzamend Neuro, Inc.



Source: <https://bigcharts.marketwatch.com/>

*Reflects a 1:15 reverse stock split in October 2023

*Reflects a 1:10 reverse stock split in July 2024

Report	Report Date	Rating	Price Target
1	9/30/2021	Buy	1,200.00
2	12/23/2021	Buy	1,237.50
3	3/16/2022	Buy	1,125.00
4	9/18/2022	Buy	1,087.50
5	12/14/2022	Buy	1,050.00
6	4/3/2023	Buy	1,012.50
7	8/9/2023	Buy	937.50
8	9/15/2023	Buy	975.00
9	12/16/2023	Buy	250.00
10	4/14/2024	Buy	210.00

- Ascendant Capital Markets, LLC has received compensation for advisory or investment banking services from the company in the past 12 months.

IMPORTANT DISCLOSURES

This report has been distributed by Ascendant Capital Markets, LLC and is for the sole use of our clients. This report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. This report contains information from various sources, including United States government publications, The Wall Street Journal and other periodicals, Yahoo! Finance and other sources, and is for informational purposes only and is not a recommendation to trade in the securities of the companies mentioned within the report. We seek to update our research and recommendations as appropriate, but the large majority of reports are published at irregular intervals as we consider appropriate and, in some cases, as constrained by industry regulations.

We may have a business relationship with companies covered in this report. Ascendant Capital Markets, LLC may make a market in the securities of the subject company. We and our affiliates, officers, directors, and employees will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered

companies referred to in this report. This report is not an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Clients should consider whether any information in this report is suitable for their particular circumstances and, if appropriate, seek professional advice, including tax advice. The price and value of the investments referred to in this report may fluctuate.

Following are some general risks that can adversely impact future operational and financial performance and share price valuation: (1) industry fundamentals with respect to legislation, mandates, incentives, customer demand, or product pricing; (2) issues relating to competing companies or products; (3) unforeseen developments with respect to management, financial condition or accounting policies or practices; or (4) external factors that affect the interest rates, currency, the economy or major segments of the economy. Past performance is not a guide to future performance, future returns are not guaranteed, and loss of original capital may occur. Certain transactions, including those involving futures, options, and other derivatives, give rise to substantial risk and are not suitable for all investors. Our report is disseminated primarily electronically, and, in some cases, in printed form. The information contained in this report is not incorporated into the contents of our website and should be read independently thereof. Copyright Ascendant Capital Markets, LLC. No part of this material may be copied, photocopied or duplicated by any means or redistributed without the prior written consent of Ascendant Capital Markets, LLC.

Risks & Considerations

Risks to attainment of our share price target include balance sheet/liquidity risks, failure of product candidates to demonstrate safety and efficacy in clinical trials, failure to gain regulatory approvals, ability to commercialize product, failure to obtain suitable reimbursement, competition, changing macroeconomic factors, investor sentiment for investing in biotech stocks, and changes in consumer or government priorities for healthcare.

Ascendant Capital Markets, LLC Rating System

BUY: We expect the stock to provide a total return of 15% or more within a 12-month period.

HOLD: We expect the stock to provide a total return of negative 15% to positive 15% within a 12-month period.

SELL: We expect the stock to have a negative total return of more than 15% within a 12-month period.

Total return is defined as price appreciation plus dividend yield.

Ascendant Capital Markets, LLC Distribution of Investment Ratings (as of July 12, 2024)

Rating	Count	Percent	Investment Banking Services Past 12 months	
			Count	Percent
Buy	58	98%	21	36%
Hold	0	0%	0	0%
Sell	1	2%	0	0%
Total	59	100%	21	36%

Other Important Disclosures

Our analysts use various valuation methodologies including discounted cash flow, price/earnings (P/E), enterprise value/EBITDAS, and P/E to growth rate, among others. Risks to our price targets include failure to achieve financial results, product risk, regulatory risk, general market conditions, and the risk of a change in economic conditions.

Dissemination of Research

Ascendant Capital Markets, LLC research is distributed electronically via the Thomson Reuters platforms, Bloomberg, Capital IQ and FactSet. Please contact your investment advisor or institutional salesperson for more information.

General Disclaimer

The information and opinions in this report were prepared by Ascendant Capital Markets, LLC. This information is not intended to be used as the primary basis of investment decisions and because of individual client objectives it should not be construed as advice designed to meet the particular investment needs of any investor. This material is for information purposes only and is not an offer or solicitation with respect to the purchase or sale of any security. The reader should assume that Ascendant Capital Markets, LLC may have a conflict of interest and should not rely solely on this report in evaluating whether or not to buy or sell securities of issuers discussed herein. The opinions, estimates, and projections contained in this report are those of Ascendant Capital Markets, LLC as of the date of this report and are subject to change without notice. Ascendant Capital Markets, LLC endeavors to ensure that the contents have been compiled or derived from sources that we believe are reliable and contain information and opinions that are accurate and complete. However, Ascendant Capital Markets, LLC makes no representation or warranty, express or implied, in respect thereof, takes no responsibility for any errors and omissions contained herein, and accepts no liability whatsoever for any loss arising from any use of, or reliance on, this report or its contents. Information may be available to Ascendant Capital Markets, LLC, or its affiliates that is not reflected in this report. This report is not to be construed as an offer or solicitation to buy or sell any security.

Additional Disclosures

Ascendant Capital Markets, LLC is a broker-dealer registered with the United States Securities and Exchange Commission (SEC) and a member of the FINRA and SIPC. Ascendant Capital Markets, LLC is not a Registered Investment Advisor nor is it an investment advisor registered with the Securities and Exchange Commission or with the securities regulators of any state, and at the present time is not eligible to file for federal registration.